Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab

J Rheumatol. 2011 Jul;38(7):1527. doi: 10.3899/jrheum.110265.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • C-Reactive Protein / metabolism
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Interleukin-6 / immunology*
  • Male
  • Middle Aged
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Severity of Illness Index
  • Spondylitis, Ankylosing / blood
  • Spondylitis, Ankylosing / drug therapy*
  • Treatment Failure
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Interleukin-6
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Infliximab
  • Adalimumab
  • tocilizumab
  • Etanercept